1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. TEMPEST THERAPEUTICS INC

Tempest Therapeutics Inc XNAS: TPST

Tempest Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Download real time

0.77 -0.07 (-8.33%)

87.17% Fall from 52W High

508.8K XNAS Volume

XNAS 28 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
Board Meeting
The next board meeting for Tempest Therapeutics Inc is on 02 Apr 2025 for the purpose of Tempest Therapeutics Inc Fourth Quarter Earnings Results for 2024 See details

Tempest Therapeutics Inc Key Metrics

Default

Market Capitalization

Below industry Median
33.6

PE TTM

Negative PE TTM
-0.9

PEG TTM

Below industry Median
0.1

Price to Book

Below industry Median
2.9

Institutional holding current Qtr %

Below industry Median
15.5

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-55.6

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-14.2

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

-13.2

ROE Annual %

Negative ROE Annual %
-131.4

RoA Annual %

Negative RoA Annual %
-60.4
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
5.8 / 100
Momentum Score
Technically Bearish
23.8 / 100
Analyst Price Target
No estimates available

10

S

14

W

5

O

0

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Tempest Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Tempest Therapeutics Inc Stock Analysis

Tempest Therapeutics Inc stock analysis with key metrics, changes, and trends.

Tempest Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$29.49 M5.19%positive

Annual Net Profit rose 5.19% in the last year to $29.49 M. Its sector's average net profit growth for the last fiscal year was -32.42%.

Price to Earning Ratio-0.95-negative

Price to Earning Ratio is -0.95, which is negative.

Stock Price$0.77-80.31%negative

Stock Price fell 80.31% and underperformed its sector by 85.98% in the past year.

Quarterly Net profit$10.56 M55.56%negative

Quarterly Net profit fell 55.56% YoY to $10.56 M. Its sector's average net profit growth YoY for the quarter was -47.39%.

Debt to Equity Ratio0.77-positive

Debt to Equity Ratio of 0.77 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-131.42 %-131.42%negative

Return on Equity(ROE) for the last financial year was -131.42%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding3.08 %0.72%positive

Mutual Fund Holding increased by 0.72% in the last quarter to 3.08.

Interest Coverage Ratio-19.35-negative

Interest Coverage Ratio is -19.35, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding15.52 %9.03%positive

Institutional Holding increased by 9.03% in the last quarter to 15.52.

VIEW LESS


Loading data..

Tempest Therapeutics Inc - Company Profile

What does Tempest Therapeutics Inc do?

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Tempest Therapeutics Inc Management structure

All Gross Remunerations are in USD
Dr. Thomas W. Dubensky, PhD
President and Director
-
2023
Gross Remuneration
Year
Mr. Stephen R. Brady
Director, Chief Executive Officer and President
-
2023
Gross Remuneration
Year

Tempest Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Dr. Thomas W. Dubensky, PhD
President and Director
-
2023
Gross Remuneration
Year
Mr. Stephen R. Brady
Director, Chief Executive Officer and President
-
2023
Gross Remuneration
Year
Dr. Thomas F. Woiwode, PhD
Independent Director
-
2023
Gross Remuneration
Year

Tempest Therapeutics Inc FAQ

How is Tempest Therapeutics Inc today?
Tempest Therapeutics Inc today is trading in the red, and is down by -8.33% at 0.77.
Tempest Therapeutics Inc is currently trading down -8.33% on an intraday basis. In the past week the stock fell -6.10%. stock has been down -8.33% in the past quarter and fell -80.31% in the past year. You can view this in the overview section.